Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Stephen Matlin, CEO of Life Length, highlights the evolution of the company over recent years, especially the establishment of their own laboratories which have allowed them to conduct clinical studies…
Against an alluring backdrop, big-name pharma brands are now starting to spend heavily on in-country manufacturing, development and shared service facilities in Spain. Spain has exceedingly high youth unemployment.…
Ramón Villamarín Valdenebro, general manager of Shionogi Spain, highlights the key steps that needed to be taken to establish the affiliate over the last 18 months and his plans to…
Javier Alvarado, general manager of Mundipharma Spain, discusses his current priorities and the innovation the company is bringing to the market through a diversified portfolio. Furthermore, he points out the…
Carlos Rus Palacios, general secretary of the Alliance of Spanish Private Healthcare (ASPE), the association of private hospitals and private health centers in Spain, delivers his message on the importance…
Maria Begona Barragan Garcia, president of GEPAC – the Spanish Group of Patients with Cancer – discusses the necessity of the group and its role in Spain’s healthcare system, in…
Yann Gaslain, CEO of Procare Health, a local player dedicated to innovative natural women’s health products, outlines his strategy to set up the company since 2012 and gives an overview…
Enrique Ordieres, president of Cinfa Group, the leading Spanish generics company, highlights the importance of diversification and internationalization in the firm’s growth strategy. He also explains the need to better…
Sergio Serra Ripol, managing director of Tillotts Pharma Spain, highlights the challenges associated with setting up the affiliate and the strategic importance of Spain as Tillotts grows its European footprint.…
Melqui Calzado, general secretary of Catalonia Bio and Health Tech, highlights the association’s strategy to establish the region as an international reference centre for innovation and entrepreneurship, as well as…
Juan Luis Fernández Balaguer, general manager of Laboratorios Combix, the Spanish affiliate of Zydus Cadila, shares the milestones achieved by the company since joining the group and its promising future…
Giuseppe Chiericatti of Chiesi Spain talks strategy, the development of the affiliate and shifting attitudes towards rare diseases in Spain. Social responsibility and sustainability is a key part of…
See our Cookie Privacy Policy Here
